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Cell therapy entails the administration of living cells that have been 
purified, propagated or differentiated to create a cell product for a 
specific therapeutic need.[1] The cell therapy industry initially involved 
only blood transfusion, haematopoietic stem cell transplantation 
(HSCT) and reproductive in vitro fertilisation,[2] but has now vastly 
expanded and will soon be one of the therapeutic pillars of healthcare 
in the 21st century.[2] Cellular therapies have also diversified over 
the years and many clinical trials are currently underway (https://
clinicaltrials.gov) to assess the safety and efficacy of various cell types 
for therapeutic use. 
One of the major cell types being investigated for therapeutic 
use is stem cells. Stem cells can be defined as a population of 
undifferentiated cells capable of asymmetric replication in which, 
with each cell division, one of the cells retains its self-renewal 
capability while the other enters a differentiation pathway and 
becomes a mature cell.[3-5] 
Stem cells can broadly be divided into three categories based on 
their differentiation potential, namely totipotent, pluripotent and 
multipotent (Fig. 1). Totipotent stem cells refer to cells with the ability 
to produce all cell types of the human body, including the placenta. 
Examples include zygotes and early blastomeres.[6] Pluripotent stem 
cells, which include embryonic stem cells and induced pluripotent 
stem cells, have the ability to differentiate into cells of the three 
embryonic germ layers (ectoderm, endoderm and mesoderm).[6,7] In 
contrast, multipotent (also called adult or somatic) stem cells are able 
to differentiate into a limited number of cell types, usually associated 
with the tissue in which they reside.[3,6] 
Adult stem cells have been identified in various tissues of 
the human body. Examples include neural stromal/stem cells, 
endometrial stromal/stem cells, mesenchymal stromal/stem cells 
(MSCs) and haematopoietic stem and progenitor cells (HSPCs).[4,8] 
MSCs have been isolated from bone marrow, the umbilical cord, 
adipose tissue and dental pulp.[9,10] The main sources of HSPCs 
are bone marrow, umbilical cord blood (UCB) and mobilised 
peripheral blood. 
HSPCs and MSCs are two of the most extensively studied adult 
stem cells in research and clinical settings. In this review we discuss 
the heterogeneous nature of HSPCs and MSCs as well as some of 
the problems associated with the expansion of these cells for use in 
therapeutic products in various clinical applications.
Heterogeneity 
Adult stem cells exist in a tightly regulated microenvironment 
(referred to as a niche) and are dispersed between differentiated cells 
in various tissues in the body.[11] As a result, the isolated cells are 
a heterogeneous population, consisting of various subpopulations, 
including a subpopulation of true stem cells. To date, there is no 
single phenotypic marker that can unambiguously identify a true 
stem cell. Thus, currently used therapeutic stem cell products are 
heterogeneous in nature.
Another aspect of heterogeneity relates to differences seen between 
primary cultures. Primary cultures can vary with regard to their 
morphology and immunophenotype, depending on, among other 
factors, species, individual, the site of isolation, age of the patient and 
the downstream processing of the cells.[12] 
Cellular heterogeneity has an important role in many biological 
processes and can be either an advantage or a hindrance in the 
research and clinical setting.
Haematopoietic stem and progenitor 
cells
HSPCs are capable of self-renewal and can differentiate into any of 
the lineages of the haematopoietic system. HSCT is a well-established 
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Fig. 1. Schematic diagram of the different categories of stem cell. 
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form of treatment for haematological 
disorders, including malignancies such as 
myeloma, lymphoma and leukaemia. In this 
setting, autologous or allogeneic transplants 
are performed to reconstitute the entire 
haematopoietic system after chemotherapy. 
A global survey by the Worldwide Network 
for Blood and Marrow Transplantation 
Group showed that the number of transplants 
(autologous and allogeneic) increased by 46% 
between 2006 and 2012 across 77 countries, 
with 46  563 transplants performed in 2006 
(20  333 allogeneic; 26  230 autologous) and 
68  146 in 2012 (31  926 allogeneic; 36  220 
autologous).[13] Transplants from matched, 
unrelated donors managed by the World 
Marrow Donor Association showed an 
increase from 7  503 allogeneic transplants 
in 2006 to 17  413 in 2012 and 21  257 
in 2017.[14] Both reports[13,14] show that 
mobolised periheral blood products have 
become the predominant source of HSPCs 
compared with bone marrow and UCB. 
Limited data exist on HSCT in the South 
African (SA) context. Global surveys show a 
90% increase overall in HSCT in the World 
Health Organization (WHO)’s African and 
Eastern Mediterranean regions from 2006 
to 2013, with a 69% and 129% increase 
in allogeneic and autologous transplants, 
respectively.[15] 
The CD34 cell surface marker is primarily 
used to identify, isolate and enumerate 
HSPCs.[16] Isolated CD34+ HSPCs are a 
heterogeneous population, which includes 
both primitive haematopoietic stem cells 
(HSCs) and early- and late-stage progenitors 
(Fig. 2). The pool of self-renewing HSCs 
has both long- and short-term repopulating 
potential, with long-term HSCs capable of 
self-renewal throughout life. In contrast, 
short-term HSCs have only limited self-
renewal capabilities. Short-term HSCs 
give rise to multipotent progenitors, which 
are precursors of common lymphoid and 
myeloid progenitors (CLP/CMP) but which 
have no self-renewal abilities. CLP progeny 
differentiate into lymphoid and natural 
killer (NK) cells. CMP progeny differentiate 
into granulocyte-macrophage progenitors 
and megakaryocyte-erythroid progenitors, 
which will differentiate into granulocytes 
and macrophages, and erythrocytes and 
megakaryocytes, respectively.[17] Heterogeneity 
of the CD34+ population is considered an 
advantage in HSCT as it ensures both short- 
and long-term engraftment. 
CD34+ cell count is generally used as 
a predictor of engraftment following HSCT.[18] 
The optimal CD34+ cell dose should be 
2.0 - 5.0 × 106/kg body weight for full 
haematopoietic recovery.[19] Several studies 
have shown that an increase in the number 
of total nucleated cells and CD34+ cells 
leads to improved engraftment in transplant 
recipients.[20] In contrast, lower cell numbers 
pose the risk of delayed haematopoietic 
recovery, which could potentially increase 
the risk of infection and necessitate patient 
hospitalisation following HSCT. One way 
to eliminate this adverse effect is through 
ex vivo expansion to increase HSPCs to 
clinically relevant numbers prior to 
transplantation. 
Expansion of HSPCs has been an area 
of interest for several years, especially 
given the difficulty in maintaining stem 
cell capabilities during this process. HSPC 
culture conditions induce spontaneous 
differentiation and loss of specific stem cell 
markers such as CD34 and CD133. Concerns 
regarding the effects of expansion have led to 
the coadministration of non-expanded and 
ex vivo expanded units during HSCT.[21-23] 
Ex vivo expansion of HSPCs has been 
achieved though different culturing methods 
at different times and with the addition of a 
variety of compounds. Cytokines were some 
of the first compounds used to expand HSPCs 
ex vivo. A major breakthrough was achieved 
when a purine derivative, StemRegenin 
1 (SR-1), was found to promote ex vivo 
expansion of CD34+ HSPCs derived from 
human UCB 50-fold and induced a 17-fold 
increase in the number of human HSPCs 
engrafting long term in immunodeficient 
mice.[24] A recent clinical study demonstrated 
improved engraftment in human recipients 
of UCB-derived CD34+ HSPCs expanded 
ex vivo with SR-1 compared with recovery 
in recipients who received equal numbers 
of CD34+ cells from the same unit but that 
were not expanded ex vivo.[22] Another study 
has shown that a pyrimidoindole derivative, 
UM171, also induces human HSPC self-
renewal and expansion ex vivo. Use of 
UM171 resulted in improved expansion of 
the more primitive human CD34+ cells from 
mobilised peripheral blood.[25] UM171 and 
SR-1 may therefore represent promising 
chemical compounds for ex vivo expansion 
of human HSPCs for clinical applications.
Mesenchymal stromal/
stem cells
MSCs are adult stem/stromal cells that 
can be isolated from numerous tissues in 
Fig. 2. Diagram of the haematopoietic hierarchy, showing all the subpopulations of cells that are CD34+ 
(NK = natural killer.)
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the human body. The International Society for Cellular Therapy 
established minimum criteria for cells to be classified as MSCs, 
including: adherence to uncoated plastic culture dishes under 
standard culture conditions; the ability of the cells to differentiate 
into osteoblasts, adipocytes and chondrocytes in vitro, and a specific 
phenotypic antigen expression profile.[26]
It is important to note that MSCs isolated and expanded in culture, 
irrespective of the tissue of isolation, are a heterogeneous population 
of cells. Surface antigen markers are not expressed exclusively on one 
cell type and therefore the specified phenotype does not reflect a 
homogeneous cell population, but rather a heterogeneous population 
of cells that share a similar phenotypic profile.
The two best studied and most widely used sources of MSCs 
are bone marrow[27] and adipose tissue.[28] MSCs derived from 
bone marrow (BM-MSCs) and adipose-derived stromal/stem cells 
(ASCs) are morphologically similar,[9,29] but differ slightly in their 
immunophenotypic profiles;[30] some of the cell surface proteins that 
are differentially expressed include CD10 (metallo-endopeptidase) 
and CD36 (fatty acid translocase).[30] Differences between the 
transcriptome profiles of these two cell types are more pronounced.[9] 
Despite their transcriptomic and immunophenotypic differences, 
both cell types were shown to have the ability to differentiate 
into osteocytes, adipocytes and chondrocytes.[9,29] However, ASCs 
showed a greater potential for adipogenesis and chondrogenesis than 
BM-MSCs and have also been reported to proliferate more rapidly.[29] 
Another advantage of ASCs over BM-MSCs is that they are abundant 
and easily accessible: per gram of tissue, up to 500 times more MSCs 
can be isolated from adipose tissue than from bone marrow.[31] 
MSCs have shown great potential in the fields of regenerative 
medicine and tissue repair. It is believed that the clinical benefit 
of MSCs lies not only in their ability to differentiate into specific 
cell types, but also in their interactions with other cells via paracrine 
signalling.[32] MSCs secrete a mixture of angiogenic, anti-inflammatory 
and anti-apoptotic cytokines.[33,34] The complex interplay of the various 
biological molecules secreted by MSCs causes the recruitment of 
other cells, which assists with the healing process.[35,36] MSCs have 
furthermore also been shown to have immunomodulatory effects 
through suppressing the proliferation and functions of T, B, NK and 
dendritic cells.[37,38]
A basic search of clinical trials with either BM-MSCs or ASCs 
between 2000 and 2019 yielded 239 studies worldwide (https://
clinicaltrials.gov). These include studies that have been completed, 
are currently active or are currently recruiting donors or volunteers. 
Studies that have been suspended, terminated or withdrawn were 
not considered in our search. Of the 239 studies, 121 involve the 
use of BM-MSCs and 118 involve the use of ASCs. The conditions 
being treated in these clinical trials are diverse; the most common 
conditions treated with BM-MSCs and/or ASCs in these trials are 
listed in Table 1. 
To our knowledge, only two licensed MSC-based products are 
available. One is Prochymal, which consists of cultured BM-MSCs 
that have been cryopreserved. It was tested by Osiris Therapeutics 
(USA) in a phase III clinical trial for patients with steroid-refractory 
graft-versus-host disease (GVHD) in 2009.[39,40] Health Canada 
subsequently approved the drug via a Notice of Compliance with 
Conditions.[39] However, Prochymal has not been distributed outside 
of clinical trials since its approval and has not been marketed as 
a treatment for steroid-refractory GVHD.[39] The other is Alofisel 
(designed by Takeda, USA), which was approved by the European 
Commission in 2018. Alofisel consists of allogeneic-cultured ASCs 
that have been cryopreserved and is used to treat enterocutaneous 
fistulae in Crohn’s disease.[39,41] 
Although MSCs have great potential and are being considered as a 
potential therapeutic product for a number of diseases, considerable 
further research is needed before MSCs can be used with confidence 
in the clinical setting. A great deal of effort is being made to better 
understand the heterogeneous nature of the isolated cell populations 
and how this heterogeneity contributes to or impedes possible clinical 
benefit. For example, many clinical trials currently using ASCs 
administer the stromal vascular fraction (SVF), which involves the 
highly heterogeneous cellular component extracted from adipose 
tissue (excluding mature adipocytes) being injected into the patient 
without culturing. As shown in Fig. 3, the SVF consists of HSPCs, 
endothelial precursor cells, endothelial cells, macrophages, smooth- 
muscle cells, lymphocytes, erythrocytes, pericytes and pre-adipocytes, 
among others.[30] 
The preferential use of the SVF in clinical trials is based largely on 
the US Food and Drug Administration’s view that cultured cells are 
considered to be a more manipulated cell therapy product. However, 
heterogeneity in these cellular populations may be a hindrance. From 
a research perspective, heterogeneity of the starting cell populations 
can increase experimental variability. This contributes to variable 
research data and may prevent reproducing reported results.[42] From 
a clinical point of view, the absence of specific markers for stem cells 
limits our ability to determine the purity of a therapeutic MSC product. 
It is hypothesised that cellular heterogeneity could decrease the 
Table 1: Most common conditions treated with mesenchymal stromal/stem cells derived from bone marrow or adipose-derived
stromal/stem cells in clinical trials, 2000 - 2019
Condition Cell type
Chron’s disease and Chron’s fistula Both
Osteoarthritis Both
Critical limb ischaemia Both
Myocardial infarction Both
Erectile dysfunction Both
Spinal cord injury Both
Amyotrophic lateral sclerosis BM-MSCs
Graft-versus-host disease (GVHD) BM-MSCs
Multiple sclerosis BM-MSCs
Fat grafts for reconstructive surgery ASCs
Chronic ischaemic heart disease ASCs
Chronic obstructive pulmonary disease ASCs
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number of functional progenitors delivered 
to diseased tissue, thus reducing treatment 
efficacy.[43] It is further hypothesised that a 
better understanding of heterogeneity may 
allow unwanted cells to be removed from 
heterogeneous populations or facilitate the 
optimum composition of cells for improved 
therapeutic efficacy to be determined.[31,43]
Both in vitro and in vivo studies have 
shown that by purifying the MSC population 
using techniques such as the side population 
assay,[44] immunophenotypic characterisation 
or single-cell transcriptome analysis,[43,45] 
the resulting subpopulations show greater 
stemness than the original, heterogeneous 
population. Using single-cell transcriptome 
technology, two research groups have 
independently identified a subpopulation 
of cells at the phenotypic level, based on 
the expression of the marker CD55. The 
one group found increased expression of 
genes related to survival, stemness and 
tissue remodelling in this subpopulation,[43] 
while the other team found their CD55+ 
subpopulation to have higher adipogenic 
differentiation capacity in vitro than the 
other subpopulations studied.[45] To our 
knowledge, purified subpopulations of MSCs 
have not yet been used in a clinical trial.
Certain clinical applications will require 
ex vivo expansion of MSCs to achieve 
clinically relevant cell numbers, which 
carries a risk of selecting for specific clones. 
The issue of clonal selection has been well 
documented[46-49] and it has been shown that 
specific clones predominate at different stages 
during the expansion process.[46,49] These 
so-called transiently contributing clones have 
varied phenotypic characteristics, which 
could influence the therapeutic efficacy of ex 
vivo expanded cells. Continuous expansion 
of a heterogeneous cell population reduces 
cell heterogeneity considerably and selects 
for single clones over time,[46] which can 
either be beneficial or limiting with regard 
to their therapeutic effect. At present, clonal 
selection cannot be controlled; therefore, the 
ever-changing clonal composition of MSC 
cultures over time during ex vivo expansion 
requires careful consideration of the cell 
culture passage number at which they are to 
be used for treatment purposes. Ideally, the 
number of ex vivo expansion rounds should 
be kept to a minimum to reduce clonal 
selection and other changes induced in the 
cell therapy product. 
The expansion of MSCs for clinical 
application requires that the isolation and 
handling procedures of the cells be compliant 
with good manufacturing practice. In most 
countries and jurisdictions, the use of 
cellular products for cell therapy is regulated 
by governmental agencies. The International 
Society for Stem Cell Research further 
published guidelines for stem cell science 
and clinical translation, which recommend 
that all reagents and processes should be 
subjected to quality-control systems and 
standard operation procedures during the 
manufacture of the cell therapy product. 
Animal-derived components used in the 
culture and preservation of cells should be 
replaced with human or chemically defined 
components. Lastly, release criteria for the 
cell product should be designed to minimise 
the risk from culture-acquired abnormalities 
such as karyotypic instabilities.[50] 
An additional aspect under investigation 
is the potential of MSCs to promote tumour 
growth. There are numerous contradictory 
studies, with some reporting that MSCs 
promote tumour growth while others report 
an inhibiting effect. Readers are referred to 
concise reviews on this topic by Klopp et al.[38] 
and Oloyo et al.[51] 
Conclusion
HSPCs and MSCs are heterogeneous 
populations that have been used successfully 
for many years (HSPCs) or have recently 
shown great potential (MSCs) in the field 
of cell therapy. The heterogeneous nature of 
HSPCs, as a standard therapeutic cell product 
in HSCT, is believed to be beneficial, as the 
various subpopulations facilitate both short- 
and long-term engraftment in the patient. 
Although MSC-based therapies are still 
experimental, clinical trials suggest the safety 
and potential efficacy of these cells as a cell 
therapy product for a wide range of diseases. 
However, there is still much to be investigated 
before MSCs can be used with confidence 
in the clinical setting. To our knowledge, all 
clinical trials thus far have been conducted 
using heterogeneous populations of cells. A 
great deal of effort is being made to better 
understand the heterogeneous nature of the 
isolated cell populations, so as to reduce 
experimental variability and clonal selection 
in MSCs grown ex vivo. It is also hypothesised 
that heterogeneity could decrease the number 
of functional progenitors delivered to diseased 
tissue, thus reducing treatment efficacy.[43] 
Strategies to isolate, purify and propagate 
subpopulations of adult stem cells may, 
therefore, contribute to the development of 
cell therapy products with enhanced clinical 
benefit in future.
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